SAN MATEO, Calif., Sept. 5, 2012 (GLOBE NEWSWIRE) -- NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX), a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies, announced today that Ronald Martell, President and Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 14th Annual Healthcare Conference to be held September 9-11, 2012, at the Waldorf Astoria Hotel in New York, NY. Mr. Martell, as well as Stephen Ghiglieri, Chief Financial Officer, will be available to respond to questions and participate in one-on-one meetings with investors.
Event: Rodman & Renshaw 14th Annual Healthcare Conference Date: Tuesday, September 11, 2012 Time: 12:05 pm ET Place: The Waldorf Astoria Hotel, New York, NY
About NeurogesX, Inc.
NeurogesX, Inc. (OTCQB:NGSX) (OTCBB:NGSX) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of novel non-opioid, pain management therapies to address unmet medical needs and improve patients' quality of life.The Company's lead product, Qutenza ®, is currently approved in the United States and the European Union. Qutenza ® is now available in the United States for the management of neuropathic pain associated with postherpetic neuralgia (PHN). In Europe, Qutenza ® is being marketed by Astellas Pharma Europe Ltd. (Astellas), the European affiliate of Tokyo-based Astellas Pharma Inc., for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain. The Company's most advanced product candidate, NGX-1998, is a topically applied liquid formulation containing a high concentration of capsaicin designed to treat pain associated with neuropathic pain conditions such as PHN. NGX-1998 has completed four Phase 1 clinical trials and one Phase 2 clinical trial in PHN patients, and the Company believes that NGX-1998 is ready to enter Phase 3 development.